个性化文献订阅>期刊> Blood
 

e-Blood High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations

  作者 Kuhn, MWM; Radtke, I; Bullinger, L; Goorha, S; Cheng, JJ; Edelmann, J; Gohlke, J; Su, XP; Paschka, P; Pounds, S; Krauter, J; Ganser, A; Quessar, A; Ribeiro, R; Gaidzik, VI; Shurtleff, S; Kronke, J; Holzmann, K; Ma, J; Schlenk, RF; Rubnitz, JE; Dohner, K; Dohner, H; Downing, JR  
  选自 期刊  Blood;  卷期  2012年119-10;  页码  E67-E75  
  关联知识点  
 

[摘要]To identify cooperating lesions in core-binding factor acute myeloid leukemia, we performed single-nucleotide polymorphism-array analysis on 300 diagnostic and 41 relapse adult and pediatric leukemia samples. We identified a mean of 1.28 copy number alterations per case at diagnosis in both patient populations. Recurrent minimally deleted regions (MDRs) were identified at 7q36.1 (7.7%), 9q21.32 (5%), 11p13 (2.3%), and 17q11.2 (2%). Approximately one-half of the 7q deletions were detectable only by single-nucleotide polymorphism-array analysis because of their limited size. Sequence analysis of MLL3, contained within the 7q36.1 MDR, in 46 diagnostic samples revealed one truncating mutation in a leukemia lacking a 7q deletion. Recurrent focal gains were identified at 8q24.21 (4.7%) and 11q25 (1.7%), both containing a single noncoding RNA. Re-current regions of copy-neutral loss-of-heterozygosity were identified at 1p (1%), 4q (0.7%), and 19p (0.7%), with known mutated cancer genes present in the minimally altered region of 1p (NRAS) and 4q (TET2). Analysis of relapse samples identified recurrent MDRs at 3q13.31 (12.2%), 5q (4.9%), and 17p (4.9%), with the 3q13.31 region containing only LSAMP, a putative tumor suppressor. Determining the role of these lesions in leukemogenesis and drug resistance should provide important insights into core-binding factor acute myeloid leukemia. (Blood. 2012;119(10):e67-e75)

 
      被申请数(0)  
 

[全文传递流程]

一般上传文献全文的时限在1个工作日内